Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke

Stockhead’s Year in Review video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. 

In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX), takes a look back on the company’s achievements in 2022.

Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.

To hear about the company’s 2022 highlights, click above.